Quinn Declan, Wigal Sharon, Swanson James, Hirsch Sharon, Ottolini Yvonne, Dariani Maghsoud, Roffman Mark, Zeldis Jerome, Cooper Thomas
Division of Child Psychiatry, Department of Psychiatry, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan Canada.
J Am Acad Child Adolesc Psychiatry. 2004 Nov;43(11):1422-9. doi: 10.1097/01.chi.0000140455.96946.2b.
Methylphenidate has four optical isomers due to two asymmetries (erythro-threo and dextro-levo). The initial commercial formulation eliminated the erythro isomer, but the dextro-levo asymmetry was racemic, with equal amounts of d and l-threo isomers (d,l-MPH). Previous work has suggested that the d-threo isomer methylphenidate (d-MPH) rather than the l-threo isomer (l-MPH) is responsible for the clinical effects in children with attention-deficit/hyperactivity disorder (ADHD). This study compared the efficacy of acute equimolar doses of d-MPH and dl-MPH in reducing ADHD symptoms over an 8-hour period in a laboratory school setting and investigated the relationship of efficacy to plasma levels of MPH.
Thirty-two children with ADHD enrolled in this double-blind, placebo-controlled, crossover study, and 31 completed the study. On seven separate occasions separated by at least 6 days, the children received a single morning dose of d-MPH (2.5, 5, or 10 mg), d,l-MPH (5, 10, or 20 mg), or placebo and then were observed in a laboratory classroom setting for 8 hours. At specified intervals, blinded observers rated behavior, and the children performed a computerized math test. The plasma levels of MPH were related to the response to study medication. The safety profiles of the two formulations were compared.
For both formulations, the responses to both MPH preparations were dose related, the plasma concentrations of l-MPH were negligible and of d-MPH were indistinguishable, and clinical efficacy was highly correlated with plasma concentrations of d-MPH. The efficacy of the d-isomer was equivalent to the racemic preparation in reducing ADHD symptoms and increasing academic productivity.
The efficacy of MPH resides in the d-isomer. The elimination of the l-isomer does not diminish the efficacy of an acute dose of methylphenidate.
由于存在两个不对称因素(赤藓糖型-苏阿糖型和右旋-左旋),哌甲酯有四种旋光异构体。最初的商业制剂去除了赤藓糖型异构体,但右旋-左旋不对称结构是外消旋的,含有等量的d型和l型苏阿糖型异构体(d,l-MPH)。先前的研究表明,在患有注意力缺陷/多动障碍(ADHD)的儿童中,d型苏阿糖型哌甲酯(d-MPH)而非l型苏阿糖型异构体(l-MPH)具有临床疗效。本研究在实验室学校环境中比较了急性等摩尔剂量的d-MPH和dl-MPH在8小时内减轻ADHD症状的疗效,并研究了疗效与MPH血浆水平的关系。
32名患有ADHD的儿童参与了这项双盲、安慰剂对照、交叉研究,31名儿童完成了研究。在至少间隔6天的七个不同时间点,儿童在早晨单次服用d-MPH(2.5、5或10毫克)、d,l-MPH(5、10或20毫克)或安慰剂,然后在实验室教室环境中观察8小时。在特定时间间隔,不知情的观察者对行为进行评分,儿童进行计算机化数学测试。MPH的血浆水平与对研究药物的反应相关。比较了两种制剂的安全性。
对于两种制剂,对两种MPH制剂的反应均与剂量相关,l-MPH的血浆浓度可忽略不计,d-MPH的血浆浓度无法区分,临床疗效与d-MPH的血浆浓度高度相关。d型异构体在减轻ADHD症状和提高学习效率方面的疗效与外消旋制剂相当。
MPH的疗效存在于d型异构体中。去除l型异构体不会降低急性剂量哌甲酯的疗效。